Cancers that
keep coming back…

Meet doctors
who never give up

Clinicians

Omico is providing free Comprehensive Genomic Profiling (CGP) to patients with advanced, incurable or an earlier diagnosis of a poor prognosis cancer, to identify potential matches to clinical trials with new targeted therapies. 

Omico is also attracting more international precision oncology trials to Australia to increase treatment options for patients.

Cancer Meet Its Match

Opportunities for the clinical community

video_icon

Why collaborate with Omico?

1

Get help finding and triaging trial options for your patients.

2

Access comprehensive genomic profiling at no cost to your patient to identify clinical trials and treatments specific to your patient’s cancer sub-type.

3

Get faster, curated and qualified recommendations.

4

Get support setting up clinical trials that may have previously been impossible due to low patient numbers.

How our genomic screening works

Appropriate patients with later-stage cancer that is not responding to current treatment or at high-risk for cancer (due to hereditary conditions):

  • You complete an online referral form
  • The patient signs a consent form
  • Cancer tissue undergoes molecular profiling
  • Molecular Tumour Board matches results to an existing therapy or clinical trial of a new drug
  • Process takes 8 to 10 weeks
More about Omico About PrOSPeCT

How Omico streamlines research

Omico is proactively screening thousands of patients with comprehensive genomic profiling to streamline clinical trial enrolment and save costs.

Standard biomarker screening

Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.

$500
per test
$50,000
per patient identified
200
specific biomarkers per $10M

Comprehensive genomic profiling

CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers for multiple trials all at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.

Annual reports About us
$2,500
per test
$25,000
per patient identified
400
specific biomarkers per $10M

Our Progress

23,906 People referred to Omico programs
11,662 Participants with a treatment recommendation, of the 17,046 who have had CGP to date (68.4%)
2,091 Participants accessing a clinical trial or matched therapy
1,388 Referring Clinicians

Referring patients to our programs

Cancer Screening Program

Our Cancer Screening Program (CaSP) brings comprehensive genomic profiling to patients with advanced and incurable cancer and helping identify potential treatments or clinical trials.

Learn more Refer a Patient

Match a patient’s molecular changes to targeted therapy

Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy or clinical trial.

Learn more

Identify the genetic basis of a patient’s cancer risk

We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.

Learn more Refer a patient
RisC and SMOC diagram

Improve the surveillance of patients at risk of multi-organ cancer

Our Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer.

Learn more Refer a patient
RisC and SMOC diagram

Learn more about the clinical trials we support

Click here for more information

FAQs

  • What will CaSP do?

    If your patient is eligible for the screening program we will:

    • Consent your patient into CaSP
    • Arrange to access tumour tissue held by a pathology centre
    • Arrange for collection of a blood sample
    • Have the tissue analysed (molecular profiling) by a NATA or CLIA/CAP accredited laboratory
    • Following review by our molecular oncology board (MOB), provide you with a report containing the tumour’s molecular profile and therapeutic recommendations including clinical trials plus a copy of the NATA report.

  • Is my patient eligible for CaSP?

    If you answer “yes” to the following statements your patient may be eligible for enrolment.

    Your patient:

    • is aged 16 years or older, with pathologically confirmed advanced and/or metastatic cancer of any histologic type or an earlier diagnosis of a poor prognosis cancer
    • has tissue available for molecular screening
    • is self-caring in all activities of daily living, and out of bed more than half of each day (ECOG performance status 0, 1 or 2)

  • How do I refer patients?

    To get your patient onto CaSP you will need to:

    • Complete the referral form (see the link below)
    • Supply a histopathology report for your patient and any relevant clinical information
    • Receive and discuss the results of the molecular screening test and MOB report with your patient
    • If appropriate refer your patient to a clinical trial or follow up on treatment options highlighted in the MOB report
    • Continue to provide us with follow up information about your patient.

    CaSP program referral form

Our network

Omico facilitates a nationwide network of research and treatment centres that facilitate, support and promote genomic cancer medicine.

CaSP optimal specimen requirements

Information and guidance to the optimal specimen requirements as part of our Cancer Screening Program (CaSP)


Download PDF resource

Work with us to help patients access genomic profiling and innovative new therapies

Get in touch